Abstract
Background: Human Papilloma virus (HPV) infections are an increasingly concerning etiology for post-transplantation viral-related malignancies. The nonavalent HPV vaccine (Gardasil 9) affords transplant recipients the best opportunity for malignancy prevention, but remains underutilized. Not previously reported for solid organ transplant recipients, we studied influential factors for HPV vaccine non-initiation. Methods: This survey, conducted from May to December 2017, examined influential factors for HPV vaccine non-initiation. HPV-related disease period prevalence was also analyzed in this regional survey. Results: Of the 164 patients approached for the study, 157 participated and 154 completed the survey resulting in a 95% response rate. Twenty-nine percent of patients within the United States Food and Drug Administration (FDA) approved age range had started or completed the HPV vaccine series at survey administration. The most significant reason for HPV vaccine non-initiation among age eligible transplant patients was a reduced physician intention to recommend. Conclusion: HPV vaccination remains underutilized in solid organ transplant patients. Emphasis on physician intention to recommend HPV vaccination will reduce vaccine non-initiation rates.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call